PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

bumetanide Side Effects

The reactions most often reported to the FDA for bumetanide (also sold as Bumex), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

25,027
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 1999 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of bumetanide come from 25,027 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 25,027 reports to the FDA Adverse Event Reporting System (FAERS) for bumetanide (Bumex): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

25,027

Reports Mentioning Death

3,999

16.0% of reports — not proof the medicine caused the death

Hospitalizations

12,100

48.3% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

DYSPNOEA
2,495
ACUTE KIDNEY INJURY
1,657
DEATH
1,642
FATIGUE
1,639
DIARRHOEA
1,474
NAUSEA
1,454
DIZZINESS
1,210
HEADACHE
1,144
RENAL FAILURE
1,133
PNEUMONIA
1,087
ASTHENIA
1,041
PAIN
1,008
HYPOTENSION
998
CARDIAC FAILURE CONGESTIVE
951
CHRONIC KIDNEY DISEASE
894
FALL
892
VOMITING
854
OEDEMA PERIPHERAL
834
MALAISE
818

Who Reports Side Effects

Gender Distribution

Female 12,977 (56%)
Male 10,257 (44%)
Unknown 40

Age Distribution

0-17 167 (1%)
18-44 952 (6%)
45-64 5,011 (29%)
65-74 4,639 (27%)
75+ 6,330 (37%)

Reporting Trend by Year

1999 2025

Reactions in Death Reports

Top reactions reported in 3,999 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 1,640
DYSPNOEA 388
RENAL FAILURE 378
ACUTE KIDNEY INJURY 312
PNEUMONIA 273
CARDIAC FAILURE CONGESTIVE 248
CARDIAC FAILURE 233
CARDIAC ARREST 205
HYPOTENSION 202
CHRONIC KIDNEY DISEASE 188
ASTHENIA 184
RESPIRATORY FAILURE 177
PAIN 175
SEPSIS 172
ATRIAL FIBRILLATION 169
FALL 166
DIARRHOEA 158
FATIGUE 151
NAUSEA 141
VOMITING 139

Reactions in Hospitalization Reports

Top reactions in 12,100 reports where hospitalization was an outcome.

Reaction Reports
DYSPNOEA 1,650
ACUTE KIDNEY INJURY 1,150
PNEUMONIA 972
FATIGUE 790
CARDIAC FAILURE CONGESTIVE 779
DIARRHOEA 761
HYPOTENSION 715
NAUSEA 714
ASTHENIA 677
FALL 658
DIZZINESS 640
RENAL FAILURE 629
ANAEMIA 570
CARDIAC FAILURE 541
VOMITING 532
OEDEMA PERIPHERAL 529
FLUID RETENTION 524
DEHYDRATION 515
HEADACHE 505
DEATH 480

Compare bumetanide vs adenosine →

What the FAERS Data Reveals About bumetanide Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 25,027 voluntary reports linked to bumetanide and its brand equivalents (Bumex), spanning 1999 through 2025. Of those, 3,999 (16.0%) listed death as an outcome and 12,100 (48.3%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 56% were female and 44% male; age distribution skews toward 75+, with 6,330 reports in that bracket. The single most reported reaction is dyspnoea with 2,495 submissions, followed by acute kidney injury and death.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.